EDSA - Edesa Biotech shares rise after reaching enrollment milestone in COVID-19 study

Edesa Biotech ([[EDSA]] +7.3%) announces that it has completed enrollment of more than 50% of the patients planned for the Phase 2 portion of its ongoing Phase 2/3 clinical study evaluating the company's EB05 drug candidate as a single-dose treatment for hospitalized COVID-19 patients with or at risk of developing Acute Respiratory Distress Syndrome ((ARDS)) - the leading cause of death in COVID-19 patients.The company reported that more than 160 of the expected 316 subjects in the Phase 2 portion of the study have been randomized and dosed with either EB05 or placebo.The company plans to activate about 20 additional hospital sites in the next two months.The international study is an adaptive, double-blind study to evaluate the efficacy and safety of EB05 in adult hospitalized COVID-19 patients. Upon promising results from the Phase 2 study, the company plans to continue with a pivotal Phase 3 trial.

For further details see:

Edesa Biotech shares rise after reaching enrollment milestone in COVID-19 study